Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04062032 · ClinicalTrials.gov registry record · Phase 2
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
A Phase 2 study of Melanoma (Skin), sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04062032 is a Phase 2 study of Melanoma (Skin) that has completed, run by University of Utah. The registered enrollment target is 41 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04062032, a Phase 2 study of Melanoma (Skin), has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.
Conditions Studied
Interventions
- DRUG Aspirin 325mg
- DRUG Aspirin 81 mg
Study Locations (1)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04062032
The ClinicalTrials.gov registry entry for NCT04062032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (70% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which Aspirin 325mg is the first listed.
NCT04062032 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT04062032 about?
NCT04062032 is a clinical study titled "Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma". This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.
What is the current status of trial NCT04062032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2016-09-27. Estimated completion is 2019-02-27.
What conditions does trial NCT04062032 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT04062032?
The interventions under investigation include: Aspirin 325mg (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT04062032?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04062032 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
COMPLETED · Phase 2
-
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
COMPLETED · Phase 2
-
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.